Q1 2023 2Seventy Bio Inc Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the 2seventy bio First Quarter 2023 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is recorded.
I would now like to turn the call over to Jenn Snyder, Head of Corporate Affairs. You may begin.
Thank you, Jayda. This afternoon, 2seventy bio issued a press release providing a business update in addition to first quarter 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 270bio.com.
Speaking on the call today are Nick Leschly, Chief Kairos Officer; Chip Baird, Chief Financial Officer; and Philip Gregory, Chief Scientific Officer; Steve Bernstein, Chief Medical Officer, is also on the call for Q&A.
As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |